Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019048629) HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/048629 International Application No.: PCT/EP2018/074186
Publication Date: 14.03.2019 International Filing Date: 07.09.2018
IPC:
A61P 35/00 (2006.01) ,A61K 31/4155 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
415
1,2-Diazoles
4155
not condensed and containing further heterocyclic rings
Applicants:
4SC AG [DE/DE]; Fraunhoferstrasse 22 82152 Planegg-Martinsried, DE
Inventors:
DANHAUSER-RIEDL, Susanne; DE
HERMANN, Frank; DE
BAUMGARTNER, Roland; DE
HAMM, Svetlana; DE
BARTZ, René; DE
Agent:
BOEHMERT & BOEHMERT; Ute Kilger Hollerallee 32 28209 Bremen, DE
Priority Data:
17190233.108.09.2017EP
17190238.008.09.2017EP
17190242.208.09.2017EP
Title (EN) HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY
(FR) INHIBITEUR DE L'HISTONE DÉSACÉTYLASE EN ASSOCIATION AVEC UN MODULATEUR DE POINT DE CONTRÔLE IMMUNITAIRE POUR LA CANCÉROTHÉRAPIE
Abstract:
(EN) The invention relates to methods, compositions and uses for the of treatment of cancer comprising the administration of an HDAC inhibitor as defined herein for the treatment of cancer in combination with at least one immune checkpoint modulator as defined herein.
(FR) L'invention concerne des méthodes, des compositions et des utilisations pour le traitement du cancer consistant à administrer un inhibiteur de l'histone désacétylase (HDAC) tel que défini dans la description pour le traitement du cancer en association avec au moins un modulateur de point de contrôle immunitaire tel que défini dans la description.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)